Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

475.517
+6.4061.37%
Number of Gainers:24
Number of Losers:25
Number of Flat:2
PE:- -
High:479.862
Open:468.227
Low:465.418
Close:469.111
Volume:368.12M
Turnover:10.79B
Market Cap:2.98T
Float Cap:2.09T

Loading ...

Xtep FY26 H1 Profit Attributable to Equity Holders Drops 10.47% to RMB 817.9 Million; Revenue Falls 0.6% to RMB 6.79 Billion

Reuters
·
Aug 25

China's Poly Property Services H1 Revenue Rises 5.2% on Property Management Services Growth

Reuters
·
Aug 25

Xtep Declares Interim Dividend of HKD 0.18 Per Share

Reuters
·
Aug 25

Xtep International Holdings - Interim Dividend of Hk18.0 Cents Per Share

THOMSON REUTERS
·
Aug 25

Xtep International Holdings H1 Net Income Attributable RMB 817.9 Million

THOMSON REUTERS
·
Aug 25

Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly

Stock News
·
Aug 25

Poly Property Services Posts H1 Net Income Attributable of Rmb933.5 MLN

Reuters
·
Aug 25

Poly Property Services FY26 H1 Profit Rises 4.3% to RMB 942.7 Million; Revenue Climbs 5.2% to RMB 8.83 Billion

Reuters
·
Aug 25

SUNAC Shares Surge Over 9% in Morning Trade Following Strategic Shift to Asset Management and Operations

Stock News
·
Aug 25

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Stock News
·
Aug 25

Hong Kong Stock Market Update | JXR Surges Over 4% in Morning Trade on Strong H1 Results and Strategic Focus on VIP and International Expansion

Stock News
·
Aug 25

The Bell Rings, $170 Billion Vanishes: Why Isn't Wang Xingxing Smiling?

Deep News
·
Aug 25

Is Xtep International Holdings (SEHK:1368) Undervalued After Its Shanghai Running Tech Launch?

Simply Wall St.
·
Aug 25

Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty

Stock News
·
Aug 25

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live
·
Aug 25

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS
·
Aug 25

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News
·
Aug 25

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Reuters
·
Aug 25

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS
·
Aug 25

Wuxi AppTec Resolves DEL Platform Security Breach, Continues Investigation With Cyber Specialists

Stock News
·
Aug 24